India’s demand for future fertilizer continues to grow
Sean Mason | April 14, 2016 | SmallCapPower
A big Indian appetite for potash boosted a small development play Thursday, while shares of software maker reached the end of the line. Here’s some small stocks making big moves on Thursday, April 14, 2016 (as of 4 pm EST):
Encanto Potash Corp. (CVE:EPO) shares climbed 100% to $0.14 on Thursday after the potash project developer announced a finalization of terms for a Memorandum of Understanding with Metals and Minerals Trading Company of India for an expanded off-take agreement for an annual supply of a minimum of 2 million metric tonnes of potash from Encanto’s Muskowekwan Project in Saskatchewan.
As well, shares of Biosign Technologies Inc. (CVE:BIO) plunged 83% to $0.005 as the healthcare software solutions developer said it has ceased its operations after Quob Park Estates confirmed it is no longer willing to advance additional funds to Biosign due to the fact that the Company cannot meet its ongoing obligations.
Oncolytics Biotech Inc. (TSE:ONC), meanwhile, reported updated results for a randomized Phase 2 clinical trial of its lead product, REOLYSIN, in combination with carboplatin and paclitaxel in patients with pancreatic cancer, which showed “a benefit in longer-term overall survival.” Oncolytics Biotech stock popped 17% to $0.52 following the announcement.
In addition, shares of DragonWave Inc. (TSE:DWI) powered 22% higher to $9.54 as the supplier of packet microwave radio systems said it has successfully completed five customer trials of the newly launched Harmony Enhanced MC dual carrier product.
Finally, theScore, Inc. (CVE:SCR) shares rose 3% to $0.305 after the creator of mobile-first sports experiences reported second-quarter revenue that increased 80% to $5.8 million.
Hi, did you know SmallCapPower accepts blog submissions? You can contact me here
The Content contained on this page (including any facts, views, opinions, recommendations, description of, or references to, products or securities) made available by SmallCapPower/Ubika Research is for information purposes only and is not tailored to the needs or circumstances of any particular person. Any mention of a particular security is merely a general discussion of the merits and risks associated there with and is not to be used or construed as an offer to sell, a solicitation of an offer to buy, or an endorsement, recommendation, or sponsorship of any entity or security by SmallCapPower/Ubika Research. The Reader should apply his/her own judgment in making any use of any Content, including, without limitation, the use of any information contained therein as the basis for any conclusions. The Reader bears responsibility for his/her own investment research and decisions. Before making any investment decision, it is strongly recommended that you seek outside advice from a qualified investment advisor. SmallCapPower/Ubika Research does not provide or guarantee any financial, legal, tax, or accounting advice or advice regarding the suitability, profitability, or potential value of any particular investment, security, or information source.